Measuring school level attributable risk to support school-based HPV vaccination programs

Background In Australia in 2017, 89% of 15-year-old females and 86% of 15-year-old males had received at least one dose of the HPV vaccine. However, considerable variation in HPV vaccination initiation (dose one) across schools remains. It is important to understand the school-level characteristics...

Full description

Saved in:
Bibliographic Details
Published inBMC public health Vol. 22; no. 1; pp. 822 - 10
Main Authors Vujovich-Dunn, C., Wand, H., Brotherton, J. M. L., Gidding, H., Sisnowski, J., Lorch, R., Veitch, M., Sheppeard, V., Effler, P., Skinner, S. R., Venn, A., Davies, C., Hocking, J., Whop, L., Leask, J., Canfell, K., Sanci, L., Smith, M., Kang, M., Temple-Smith, M., Kidd, M., Burns, S., Selvey, L., Meijer, D., Ennis, S., Thomson, C., Lane, N., Kaldor, J., Guy, R.
Format Journal Article
LanguageEnglish
Published London BioMed Central 25.04.2022
BioMed Central Ltd
BMC
Subjects
Online AccessGet full text
ISSN1471-2458
1471-2458
DOI10.1186/s12889-022-13088-x

Cover

Abstract Background In Australia in 2017, 89% of 15-year-old females and 86% of 15-year-old males had received at least one dose of the HPV vaccine. However, considerable variation in HPV vaccination initiation (dose one) across schools remains. It is important to understand the school-level characteristics most strongly associated with low initiation and their contribution to the overall between-school variation. Methods A population-based ecological analysis was conducted using school-level data for 2016 on all adolescent students eligible for HPV vaccination in three Australian jurisdictions. We conducted logistic regression to determine school-level factors associated with lower HPV vaccination initiation (< 75% dose 1 uptake) and estimated the population attributable risk (PAR) and the proportion of schools with the factor (school-level prevalence). Results The factors most strongly associated with lower initiation, and their prevalence were; small schools (OR = 9.3, 95%CI = 6.1–14.1; 33% of schools), special education schools (OR = 5.6,95%CI = 3.7–8.5; 8% of schools), higher Indigenous enrolments (OR = 2.7,95% CI:1.9–3.7; 31% of schools), lower attendance rates (OR = 2.6,95%CI = 1.7–3.7; 35% of schools), remote location (OR = 2.6,95%CI = 1.6–4.3; 6% of schools,) and lower socioeconomic area (OR = 1.8,95% CI = 1.3–2.5; 33% of schools). The highest PARs were small schools (PAR = 79%, 95%CI:76–82), higher Indigenous enrolments (PAR = 38%, 95%CI: 31–44) and lower attendance rate (PAR = 37%, 95%CI: 29–46). Conclusion This analysis suggests that initiatives to support schools that are smaller, with a higher proportion of Indigenous adolescents and lower attendance rates may contribute most to reducing the variation of HPV vaccination uptake observed at a school-level in these jurisdictions. Estimating population-level coverage at the school-level is useful to guide policy and prioritise resourcing to support school-based vaccination programs.
AbstractList In Australia in 2017, 89% of 15-year-old females and 86% of 15-year-old males had received at least one dose of the HPV vaccine. However, considerable variation in HPV vaccination initiation (dose one) across schools remains. It is important to understand the school-level characteristics most strongly associated with low initiation and their contribution to the overall between-school variation. A population-based ecological analysis was conducted using school-level data for 2016 on all adolescent students eligible for HPV vaccination in three Australian jurisdictions. We conducted logistic regression to determine school-level factors associated with lower HPV vaccination initiation (< 75% dose 1 uptake) and estimated the population attributable risk (PAR) and the proportion of schools with the factor (school-level prevalence). The factors most strongly associated with lower initiation, and their prevalence were; small schools (OR = 9.3, 95%CI = 6.1-14.1; 33% of schools), special education schools (OR = 5.6,95%CI = 3.7-8.5; 8% of schools), higher Indigenous enrolments (OR = 2.7,95% CI:1.9-3.7; 31% of schools), lower attendance rates (OR = 2.6,95%CI = 1.7-3.7; 35% of schools), remote location (OR = 2.6,95%CI = 1.6-4.3; 6% of schools,) and lower socioeconomic area (OR = 1.8,95% CI = 1.3-2.5; 33% of schools). The highest PARs were small schools (PAR = 79%, 95%CI:76-82), higher Indigenous enrolments (PAR = 38%, 95%CI: 31-44) and lower attendance rate (PAR = 37%, 95%CI: 29-46). This analysis suggests that initiatives to support schools that are smaller, with a higher proportion of Indigenous adolescents and lower attendance rates may contribute most to reducing the variation of HPV vaccination uptake observed at a school-level in these jurisdictions. Estimating population-level coverage at the school-level is useful to guide policy and prioritise resourcing to support school-based vaccination programs.
Background In Australia in 2017, 89% of 15-year-old females and 86% of 15-year-old males had received at least one dose of the HPV vaccine. However, considerable variation in HPV vaccination initiation (dose one) across schools remains. It is important to understand the school-level characteristics most strongly associated with low initiation and their contribution to the overall between-school variation. Methods A population-based ecological analysis was conducted using school-level data for 2016 on all adolescent students eligible for HPV vaccination in three Australian jurisdictions. We conducted logistic regression to determine school-level factors associated with lower HPV vaccination initiation (< 75% dose 1 uptake) and estimated the population attributable risk (PAR) and the proportion of schools with the factor (school-level prevalence). Results The factors most strongly associated with lower initiation, and their prevalence were; small schools (OR = 9.3, 95%CI = 6.1–14.1; 33% of schools), special education schools (OR = 5.6,95%CI = 3.7–8.5; 8% of schools), higher Indigenous enrolments (OR = 2.7,95% CI:1.9–3.7; 31% of schools), lower attendance rates (OR = 2.6,95%CI = 1.7–3.7; 35% of schools), remote location (OR = 2.6,95%CI = 1.6–4.3; 6% of schools,) and lower socioeconomic area (OR = 1.8,95% CI = 1.3–2.5; 33% of schools). The highest PARs were small schools (PAR = 79%, 95%CI:76–82), higher Indigenous enrolments (PAR = 38%, 95%CI: 31–44) and lower attendance rate (PAR = 37%, 95%CI: 29–46). Conclusion This analysis suggests that initiatives to support schools that are smaller, with a higher proportion of Indigenous adolescents and lower attendance rates may contribute most to reducing the variation of HPV vaccination uptake observed at a school-level in these jurisdictions. Estimating population-level coverage at the school-level is useful to guide policy and prioritise resourcing to support school-based vaccination programs.
Background In Australia in 2017, 89% of 15-year-old females and 86% of 15-year-old males had received at least one dose of the HPV vaccine. However, considerable variation in HPV vaccination initiation (dose one) across schools remains. It is important to understand the school-level characteristics most strongly associated with low initiation and their contribution to the overall between-school variation. Methods A population-based ecological analysis was conducted using school-level data for 2016 on all adolescent students eligible for HPV vaccination in three Australian jurisdictions. We conducted logistic regression to determine school-level factors associated with lower HPV vaccination initiation (< 75% dose 1 uptake) and estimated the population attributable risk (PAR) and the proportion of schools with the factor (school-level prevalence). Results The factors most strongly associated with lower initiation, and their prevalence were; small schools (OR = 9.3, 95%CI = 6.1–14.1; 33% of schools), special education schools (OR = 5.6,95%CI = 3.7–8.5; 8% of schools), higher Indigenous enrolments (OR = 2.7,95% CI:1.9–3.7; 31% of schools), lower attendance rates (OR = 2.6,95%CI = 1.7–3.7; 35% of schools), remote location (OR = 2.6,95%CI = 1.6–4.3; 6% of schools,) and lower socioeconomic area (OR = 1.8,95% CI = 1.3–2.5; 33% of schools). The highest PARs were small schools (PAR = 79%, 95%CI:76–82), higher Indigenous enrolments (PAR = 38%, 95%CI: 31–44) and lower attendance rate (PAR = 37%, 95%CI: 29–46). Conclusion This analysis suggests that initiatives to support schools that are smaller, with a higher proportion of Indigenous adolescents and lower attendance rates may contribute most to reducing the variation of HPV vaccination uptake observed at a school-level in these jurisdictions. Estimating population-level coverage at the school-level is useful to guide policy and prioritise resourcing to support school-based vaccination programs.
In Australia in 2017, 89% of 15-year-old females and 86% of 15-year-old males had received at least one dose of the HPV vaccine. However, considerable variation in HPV vaccination initiation (dose one) across schools remains. It is important to understand the school-level characteristics most strongly associated with low initiation and their contribution to the overall between-school variation. A population-based ecological analysis was conducted using school-level data for 2016 on all adolescent students eligible for HPV vaccination in three Australian jurisdictions. We conducted logistic regression to determine school-level factors associated with lower HPV vaccination initiation (< 75% dose 1 uptake) and estimated the population attributable risk (PAR) and the proportion of schools with the factor (school-level prevalence). The factors most strongly associated with lower initiation, and their prevalence were; small schools (OR = 9.3, 95%CI = 6.1-14.1; 33% of schools), special education schools (OR = 5.6,95%CI = 3.7-8.5; 8% of schools), higher Indigenous enrolments (OR = 2.7,95% CI:1.9-3.7; 31% of schools), lower attendance rates (OR = 2.6,95%CI = 1.7-3.7; 35% of schools), remote location (OR = 2.6,95%CI = 1.6-4.3; 6% of schools,) and lower socioeconomic area (OR = 1.8,95% CI = 1.3-2.5; 33% of schools). The highest PARs were small schools (PAR = 79%, 95%CI:76-82), higher Indigenous enrolments (PAR = 38%, 95%CI: 31-44) and lower attendance rate (PAR = 37%, 95%CI: 29-46). This analysis suggests that initiatives to support schools that are smaller, with a higher proportion of Indigenous adolescents and lower attendance rates may contribute most to reducing the variation of HPV vaccination uptake observed at a school-level in these jurisdictions. Estimating population-level coverage at the school-level is useful to guide policy and prioritise resourcing to support school-based vaccination programs.
Background In Australia in 2017, 89% of 15-year-old females and 86% of 15-year-old males had received at least one dose of the HPV vaccine. However, considerable variation in HPV vaccination initiation (dose one) across schools remains. It is important to understand the school-level characteristics most strongly associated with low initiation and their contribution to the overall between-school variation. Methods A population-based ecological analysis was conducted using school-level data for 2016 on all adolescent students eligible for HPV vaccination in three Australian jurisdictions. We conducted logistic regression to determine school-level factors associated with lower HPV vaccination initiation (< 75% dose 1 uptake) and estimated the population attributable risk (PAR) and the proportion of schools with the factor (school-level prevalence). Results The factors most strongly associated with lower initiation, and their prevalence were; small schools (OR = 9.3, 95%CI = 6.1-14.1; 33% of schools), special education schools (OR = 5.6,95%CI = 3.7-8.5; 8% of schools), higher Indigenous enrolments (OR = 2.7,95% CI:1.9-3.7; 31% of schools), lower attendance rates (OR = 2.6,95%CI = 1.7-3.7; 35% of schools), remote location (OR = 2.6,95%CI = 1.6-4.3; 6% of schools,) and lower socioeconomic area (OR = 1.8,95% CI = 1.3-2.5; 33% of schools). The highest PARs were small schools (PAR = 79%, 95%CI:76-82), higher Indigenous enrolments (PAR = 38%, 95%CI: 31-44) and lower attendance rate (PAR = 37%, 95%CI: 29-46). Conclusion This analysis suggests that initiatives to support schools that are smaller, with a higher proportion of Indigenous adolescents and lower attendance rates may contribute most to reducing the variation of HPV vaccination uptake observed at a school-level in these jurisdictions. Estimating population-level coverage at the school-level is useful to guide policy and prioritise resourcing to support school-based vaccination programs. Keywords: HPV vaccines, Primary prevention, Cervical cancer, Immunisation programs, School-based, Health equity
In Australia in 2017, 89% of 15-year-old females and 86% of 15-year-old males had received at least one dose of the HPV vaccine. However, considerable variation in HPV vaccination initiation (dose one) across schools remains. It is important to understand the school-level characteristics most strongly associated with low initiation and their contribution to the overall between-school variation.BACKGROUNDIn Australia in 2017, 89% of 15-year-old females and 86% of 15-year-old males had received at least one dose of the HPV vaccine. However, considerable variation in HPV vaccination initiation (dose one) across schools remains. It is important to understand the school-level characteristics most strongly associated with low initiation and their contribution to the overall between-school variation.A population-based ecological analysis was conducted using school-level data for 2016 on all adolescent students eligible for HPV vaccination in three Australian jurisdictions. We conducted logistic regression to determine school-level factors associated with lower HPV vaccination initiation (< 75% dose 1 uptake) and estimated the population attributable risk (PAR) and the proportion of schools with the factor (school-level prevalence).METHODSA population-based ecological analysis was conducted using school-level data for 2016 on all adolescent students eligible for HPV vaccination in three Australian jurisdictions. We conducted logistic regression to determine school-level factors associated with lower HPV vaccination initiation (< 75% dose 1 uptake) and estimated the population attributable risk (PAR) and the proportion of schools with the factor (school-level prevalence).The factors most strongly associated with lower initiation, and their prevalence were; small schools (OR = 9.3, 95%CI = 6.1-14.1; 33% of schools), special education schools (OR = 5.6,95%CI = 3.7-8.5; 8% of schools), higher Indigenous enrolments (OR = 2.7,95% CI:1.9-3.7; 31% of schools), lower attendance rates (OR = 2.6,95%CI = 1.7-3.7; 35% of schools), remote location (OR = 2.6,95%CI = 1.6-4.3; 6% of schools,) and lower socioeconomic area (OR = 1.8,95% CI = 1.3-2.5; 33% of schools). The highest PARs were small schools (PAR = 79%, 95%CI:76-82), higher Indigenous enrolments (PAR = 38%, 95%CI: 31-44) and lower attendance rate (PAR = 37%, 95%CI: 29-46).RESULTSThe factors most strongly associated with lower initiation, and their prevalence were; small schools (OR = 9.3, 95%CI = 6.1-14.1; 33% of schools), special education schools (OR = 5.6,95%CI = 3.7-8.5; 8% of schools), higher Indigenous enrolments (OR = 2.7,95% CI:1.9-3.7; 31% of schools), lower attendance rates (OR = 2.6,95%CI = 1.7-3.7; 35% of schools), remote location (OR = 2.6,95%CI = 1.6-4.3; 6% of schools,) and lower socioeconomic area (OR = 1.8,95% CI = 1.3-2.5; 33% of schools). The highest PARs were small schools (PAR = 79%, 95%CI:76-82), higher Indigenous enrolments (PAR = 38%, 95%CI: 31-44) and lower attendance rate (PAR = 37%, 95%CI: 29-46).This analysis suggests that initiatives to support schools that are smaller, with a higher proportion of Indigenous adolescents and lower attendance rates may contribute most to reducing the variation of HPV vaccination uptake observed at a school-level in these jurisdictions. Estimating population-level coverage at the school-level is useful to guide policy and prioritise resourcing to support school-based vaccination programs.CONCLUSIONThis analysis suggests that initiatives to support schools that are smaller, with a higher proportion of Indigenous adolescents and lower attendance rates may contribute most to reducing the variation of HPV vaccination uptake observed at a school-level in these jurisdictions. Estimating population-level coverage at the school-level is useful to guide policy and prioritise resourcing to support school-based vaccination programs.
Abstract Background In Australia in 2017, 89% of 15-year-old females and 86% of 15-year-old males had received at least one dose of the HPV vaccine. However, considerable variation in HPV vaccination initiation (dose one) across schools remains. It is important to understand the school-level characteristics most strongly associated with low initiation and their contribution to the overall between-school variation. Methods A population-based ecological analysis was conducted using school-level data for 2016 on all adolescent students eligible for HPV vaccination in three Australian jurisdictions. We conducted logistic regression to determine school-level factors associated with lower HPV vaccination initiation (< 75% dose 1 uptake) and estimated the population attributable risk (PAR) and the proportion of schools with the factor (school-level prevalence). Results The factors most strongly associated with lower initiation, and their prevalence were; small schools (OR = 9.3, 95%CI = 6.1–14.1; 33% of schools), special education schools (OR = 5.6,95%CI = 3.7–8.5; 8% of schools), higher Indigenous enrolments (OR = 2.7,95% CI:1.9–3.7; 31% of schools), lower attendance rates (OR = 2.6,95%CI = 1.7–3.7; 35% of schools), remote location (OR = 2.6,95%CI = 1.6–4.3; 6% of schools,) and lower socioeconomic area (OR = 1.8,95% CI = 1.3–2.5; 33% of schools). The highest PARs were small schools (PAR = 79%, 95%CI:76–82), higher Indigenous enrolments (PAR = 38%, 95%CI: 31–44) and lower attendance rate (PAR = 37%, 95%CI: 29–46). Conclusion This analysis suggests that initiatives to support schools that are smaller, with a higher proportion of Indigenous adolescents and lower attendance rates may contribute most to reducing the variation of HPV vaccination uptake observed at a school-level in these jurisdictions. Estimating population-level coverage at the school-level is useful to guide policy and prioritise resourcing to support school-based vaccination programs.
ArticleNumber 822
Audience Academic
Author Leask, J.
Venn, A.
Selvey, L.
Veitch, M.
Guy, R.
Sanci, L.
Sisnowski, J.
Kaldor, J.
Kang, M.
Sheppeard, V.
Lane, N.
Vujovich-Dunn, C.
Lorch, R.
Canfell, K.
Kidd, M.
Davies, C.
Gidding, H.
Effler, P.
Whop, L.
Meijer, D.
Burns, S.
Smith, M.
Brotherton, J. M. L.
Ennis, S.
Hocking, J.
Wand, H.
Skinner, S. R.
Thomson, C.
Temple-Smith, M.
Author_xml – sequence: 1
  givenname: C.
  surname: Vujovich-Dunn
  fullname: Vujovich-Dunn, C.
  email: cvujovich-dunn@kirby.unsw.edu.au
  organization: University of New South Wales, Kirby Institute
– sequence: 2
  givenname: H.
  surname: Wand
  fullname: Wand, H.
  organization: University of New South Wales, Kirby Institute
– sequence: 3
  givenname: J. M. L.
  surname: Brotherton
  fullname: Brotherton, J. M. L.
  organization: Australian Centre for the Prevention of Cervical Cancer, Population Health, University of Melbourne, Melbourne School of Population and Global Health
– sequence: 4
  givenname: H.
  surname: Gidding
  fullname: Gidding, H.
  organization: University of Sydney, Northern Clinical School, Women and Babies Research, Kolling Institute, Northern Sydney Local Health District, School of Population Health, University of New South Wales, National Centre for Immunisation Research and Surveillance
– sequence: 5
  givenname: J.
  surname: Sisnowski
  fullname: Sisnowski, J.
  organization: University of New South Wales, Kirby Institute, Australian National University, National Centre for Epidemiology & Population Health
– sequence: 6
  givenname: R.
  surname: Lorch
  fullname: Lorch, R.
  organization: University of New South Wales, Kirby Institute
– sequence: 7
  givenname: M.
  surname: Veitch
  fullname: Veitch, M.
  organization: Department of Health and Human Services, Tasmanian Government
– sequence: 8
  givenname: V.
  surname: Sheppeard
  fullname: Sheppeard, V.
  organization: Communicable Diseases Branch, NSW Health, University of Sydney, Sydney School of Public Health
– sequence: 9
  givenname: P.
  surname: Effler
  fullname: Effler, P.
  organization: Communicable Disease Control Directorate, Department of Health
– sequence: 10
  givenname: S. R.
  surname: Skinner
  fullname: Skinner, S. R.
  organization: University of Sydney, Specialty of Child and Adolescent Health, Faculty of Medicine and Health, Children’s Hospital Westmead, Sydney Children’s Hospitals Network
– sequence: 11
  givenname: A.
  surname: Venn
  fullname: Venn, A.
  organization: Menzies Institute for Medical Research, University of Tasmania
– sequence: 12
  givenname: C.
  surname: Davies
  fullname: Davies, C.
  organization: University of Sydney, Specialty of Child and Adolescent Health, Faculty of Medicine and Health, Children’s Hospital Westmead, Sydney Children’s Hospitals Network
– sequence: 13
  givenname: J.
  surname: Hocking
  fullname: Hocking, J.
  organization: University of Melbourne, Melbourne School of Population and Global Health
– sequence: 14
  givenname: L.
  surname: Whop
  fullname: Whop, L.
  organization: Australian National University, National Centre for Epidemiology & Population Health, Menzies School of Health Research, Charles Darwin University
– sequence: 15
  givenname: J.
  surname: Leask
  fullname: Leask, J.
  organization: National Centre for Immunisation Research and Surveillance, University of Sydney, Sydney Nursing School, Faculty of Medicine and Health
– sequence: 16
  givenname: K.
  surname: Canfell
  fullname: Canfell, K.
  organization: The Daffodil Centre, University of Sydney, A Joint Venture With Cancer Council NSW
– sequence: 17
  givenname: L.
  surname: Sanci
  fullname: Sanci, L.
  organization: University of Melbourne, Medicine, Dentistry and Health Sciences
– sequence: 18
  givenname: M.
  surname: Smith
  fullname: Smith, M.
  organization: The Daffodil Centre, University of Sydney, A Joint Venture With Cancer Council NSW, School of Public Health, University of Sydney
– sequence: 19
  givenname: M.
  surname: Kang
  fullname: Kang, M.
  organization: University of Sydney, Westmead Clinical School
– sequence: 20
  givenname: M.
  surname: Temple-Smith
  fullname: Temple-Smith, M.
  organization: University of Melbourne, Medicine, Dentistry and Health Sciences
– sequence: 21
  givenname: M.
  surname: Kidd
  fullname: Kidd, M.
  organization: Flinders University, Southgate Institute for Health, Society and Equity
– sequence: 22
  givenname: S.
  surname: Burns
  fullname: Burns, S.
  organization: Curtin University, School of Population Health
– sequence: 23
  givenname: L.
  surname: Selvey
  fullname: Selvey, L.
  organization: University of Queensland, School of Public Health
– sequence: 24
  givenname: D.
  surname: Meijer
  fullname: Meijer, D.
  organization: Immunisation Unit, Health Protection NSW, St Leonard’s
– sequence: 25
  givenname: S.
  surname: Ennis
  fullname: Ennis, S.
  organization: Immunisation Unit, Health Protection NSW, St Leonard’s
– sequence: 26
  givenname: C.
  surname: Thomson
  fullname: Thomson, C.
  organization: Communicable Disease Control Directorate, Department of Health
– sequence: 27
  givenname: N.
  surname: Lane
  fullname: Lane, N.
  organization: Department of Health and Human Services, Tasmanian Government
– sequence: 28
  givenname: J.
  surname: Kaldor
  fullname: Kaldor, J.
  organization: University of New South Wales, Kirby Institute
– sequence: 29
  givenname: R.
  surname: Guy
  fullname: Guy, R.
  organization: University of New South Wales, Kirby Institute
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35468743$$D View this record in MEDLINE/PubMed
BookMark eNp9kktv1DAUhSNURB_wB1igSGzYpPgV29kgVVWhlYpgAUisLNu5ST1k4mA7o_Lv8TxKOxWqvbBln_NZ9_ocFwejH6EoXmN0irHk7yMmUjYVIqTCFElZ3T4rjjATuCKslgcP9ofFcYwLhLCQNXlRHNKacSkYPSp-fgYd5-DGvoz2xvuhHGAFQ6lTCs7MSZsByuDirzL5Ms7T5EPaKSujI7Tl5dcf5Upb60adnB_LKfg-6GV8WTzv9BDh1W49Kb5_vPh2flldf_l0dX52XVmORKpACMGRlQ1GEhgWuBGGc9w2wEEzySi0lujWUEEYNcxwgmoragK1BYOajp4UV1tu6_VCTcEtdfijvHZqc-BDr3RIzg6gWNtyrSnqmow2tTG4bVtBRAcUCIcmsz5sWdNslvlhGFPQwx50_2Z0N6r3K9UgynM_M-DdDhD87xliUksXLQyDHsHPURFe1zVHXPAsfftIuvBzGHOrsmo9BG-ae1WvcwFu7Hx-166h6kwgzHHDpMyq0_-o8mxh6WxOTefy-Z7hzcNC_1V4F4wskFuBDT7GAJ2yLm0-OJPdoDBS6wyqbQZVzqDaZFDdZit5ZL2jP2miW1Oc1mGEcN-NJ1x_AYvx7z0
CitedBy_id crossref_primary_10_1080_14681811_2022_2084373
crossref_primary_10_3390_vaccines12080922
crossref_primary_10_1111_josh_70003
crossref_primary_10_3390_vaccines12080888
crossref_primary_10_1016_j_vaccine_2024_07_048
crossref_primary_10_1016_j_ypmed_2023_107542
crossref_primary_10_1186_s12889_024_19322_y
crossref_primary_10_4103_ijmr_ijmr_1052_23
crossref_primary_10_3390_pathogens12121380
crossref_primary_10_3389_fimmu_2023_1150238
crossref_primary_10_1016_j_mcna_2023_05_012
Cites_doi 10.1080/21645515.2019.1640556
10.1016/S0140-6736(11)60551-5
10.3390/vaccines9070687
10.1136/sti.2009.040188
10.1093/ije/29.5.813
10.1136/bmjopen-2014-006422
10.1071/SH09140
10.1016/j.vaccine.2016.01.061
10.1111/1753-6405.12218
10.4103/2229-5070.175024
10.1542/peds.101.6.970
10.3109/13668250.2017.1310827
10.1111/jpc.12030
10.1136/bmj.39541.534109.BE
10.1016/j.vaccine.2014.01.081
10.1016/S0140-6736(19)30298-3
10.1093/pubmed/fdaa164
10.1002/ijc.30716
10.1016/j.ejca.2017.05.026
10.18590/mjm.2017.vol3.iss2.8
10.1056/NEJMoa1917338
10.1016/S2468-2667(16)30001-9
10.1016/j.vaccine.2021.08.076
10.1016/j.vaccine.2010.04.038
10.1136/bmjopen-2019-029087
10.1016/S2214-109X(19)30482-6
10.1016/S0140-6736(20)30068-4
10.5694/mja11.11360
10.1016/j.vaccine.2018.11.034
10.1007/978-1-4020-5614-7_2685
10.1080/14760584.2018.1548282
10.1200/JGO.2016.008151
10.1016/S2214-109X(16)30099-7
10.1017/S095026881000066X
10.1186/s12889-016-3195-6
10.1136/jech-2013-202629
10.3390/ijerph17217997
10.5694/mja2.50221
10.1136/bmj.f2032
10.1111/1753-6405.12149
10.1371/journal.pmed.1000270
10.3109/13625180903229605
10.1002/cncr.29954
10.1093/pubmed/fdt042
10.5694/mja16.00597
10.1186/1741-7015-11-227
10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
10.1016/S1470-2045(12)70137-7
10.3111/13696998.2013.793691
10.1136/jech-2013-202620
ContentType Journal Article
Copyright The Author(s) 2022
2022. The Author(s).
COPYRIGHT 2022 BioMed Central Ltd.
2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2022
– notice: 2022. The Author(s).
– notice: COPYRIGHT 2022 BioMed Central Ltd.
– notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7T2
7X7
7XB
88E
8C1
8FE
8FG
8FI
8FJ
8FK
ABJCF
ABUWG
AEUYN
AFKRA
AN0
ATCPS
AZQEC
BENPR
BGLVJ
BHPHI
C1K
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
L6V
M0S
M1P
M7S
PATMY
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
PTHSS
PYCSY
7X8
5PM
DOA
DOI 10.1186/s12889-022-13088-x
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health and Safety Science Abstracts (Full archive)
Health & Medical Collection (ProQuest)
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Public Health Database (ProQuest)
ProQuest SciTech Collection
ProQuest Technology Collection
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
Materials Science & Engineering Collection (subscription)
ProQuest Central (Alumni)
ProQuest One Sustainability (subscription)
ProQuest Central UK/Ireland
British Nursing Database
Agricultural & Environmental Science Collection
ProQuest Central Essentials
ProQuest Central
Technology Collection (via ProQuest SciTech Premium Collection)
ProQuest Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Collection (ProQuest)
ProQuest Health & Medical Complete (Alumni)
ProQuest Engineering Collection
Health & Medical Collection (Alumni)
Medical Database ProQuest
Engineering Database
Environmental Science Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
Engineering collection
Environmental Science Collection
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
Technology Collection
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
Environmental Sciences and Pollution Management
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
ProQuest Health & Medical Research Collection
ProQuest Engineering Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Agricultural & Environmental Science Collection
Health & Safety Science Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Engineering Collection
Engineering Database
ProQuest Public Health
ProQuest One Academic Eastern Edition
British Nursing Index with Full Text
ProQuest Hospital Collection
ProQuest Technology Collection
Health Research Premium Collection (Alumni)
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
Environmental Science Collection
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Materials Science & Engineering Collection
Environmental Science Database
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE
Publicly Available Content Database



MEDLINE - Academic

Database_xml – sequence: 1
  dbid: C6C
  name: SpringerOpen Free (Free internet resource, activated by CARLI)
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: 8FG
  name: ProQuest Technology Collection
  url: https://search.proquest.com/technologycollection1
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Public Health
EISSN 1471-2458
EndPage 10
ExternalDocumentID oai_doaj_org_article_4dd6aa30f9ea4b5bb1ddd727fe3e26e9
PMC9036743
A701619488
35468743
10_1186_s12889_022_13088_x
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations Australia
United Kingdom
Canada
United States--US
Western Australia Australia
New South Wales Australia
Tasmania Australia
GeographicLocations_xml – name: Australia
– name: United Kingdom
– name: Tasmania Australia
– name: Canada
– name: New South Wales Australia
– name: United States--US
– name: Western Australia Australia
GroupedDBID ---
0R~
23N
2WC
2XV
44B
53G
5VS
6J9
6PF
7X7
7XC
88E
8C1
8FE
8FG
8FH
8FI
8FJ
A8Z
AAFWJ
AAJSJ
AASML
AAWTL
ABDBF
ABJCF
ABUWG
ACGFO
ACGFS
ACIHN
ACIWK
ACPRK
ACUHS
ADBBV
ADUKV
AEAQA
AENEX
AEUYN
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AN0
AOIJS
ATCPS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BGLVJ
BHPHI
BMC
BNQBC
BPHCQ
BVXVI
C6C
CCPQU
CS3
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EMB
EMK
EMOBN
ESTFP
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HCIFZ
HMCUK
HYE
IAO
IHR
INH
INR
ITC
KQ8
L6V
M1P
M48
M7S
M~E
O5R
O5S
OK1
OVT
P2P
PATMY
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PQGLB
PQQKQ
PROAC
PSQYO
PTHSS
PUEGO
PYCSY
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
TUS
U2A
UKHRP
W2D
WOQ
WOW
XSB
AAYXX
ALIPV
CITATION
-A0
3V.
ACRMQ
ADINQ
C24
CGR
CUY
CVF
ECM
EIF
NPM
PMFND
7T2
7XB
8FK
AZQEC
C1K
DWQXO
GNUQQ
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c607t-e77760c89108e417197b661d9e6ea4843edc2adb37243b4b6205c752e5ceb09f3
IEDL.DBID BENPR
ISSN 1471-2458
IngestDate Wed Aug 27 01:31:26 EDT 2025
Thu Aug 21 14:19:54 EDT 2025
Mon Sep 08 14:27:51 EDT 2025
Fri Jul 25 18:59:23 EDT 2025
Tue Jun 17 21:27:21 EDT 2025
Tue Jun 10 20:10:56 EDT 2025
Wed Feb 19 02:25:59 EST 2025
Thu Apr 24 22:59:30 EDT 2025
Tue Jul 01 00:56:31 EDT 2025
Sat Sep 06 07:29:12 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Health equity
HPV vaccines
Primary prevention
Immunisation programs
School-based
Cervical cancer
Language English
License 2022. The Author(s).
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c607t-e77760c89108e417197b661d9e6ea4843edc2adb37243b4b6205c752e5ceb09f3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://www.proquest.com/docview/2666667699?pq-origsite=%requestingapplication%&accountid=15518
PMID 35468743
PQID 2666667699
PQPubID 44782
PageCount 10
ParticipantIDs doaj_primary_oai_doaj_org_article_4dd6aa30f9ea4b5bb1ddd727fe3e26e9
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9036743
proquest_miscellaneous_2655560676
proquest_journals_2666667699
gale_infotracmisc_A701619488
gale_infotracacademiconefile_A701619488
pubmed_primary_35468743
crossref_citationtrail_10_1186_s12889_022_13088_x
crossref_primary_10_1186_s12889_022_13088_x
springer_journals_10_1186_s12889_022_13088_x
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-04-25
PublicationDateYYYYMMDD 2022-04-25
PublicationDate_xml – month: 04
  year: 2022
  text: 2022-04-25
  day: 25
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle BMC public health
PublicationTitleAbbrev BMC Public Health
PublicationTitleAlternate BMC Public Health
PublicationYear 2022
Publisher BioMed Central
BioMed Central Ltd
BMC
Publisher_xml – name: BioMed Central
– name: BioMed Central Ltd
– name: BMC
References BPXZ Yawn (13088_CR41) 2000; 13
A Acampora (13088_CR60) 2020; 17
B Feiring (13088_CR36) 2015; 5
E Préaud (13088_CR6) 2013; 16
13088_CR19
M Arbyn (13088_CR18) 2018; 17
13088_CR16
H Ali (13088_CR10) 2013; 346
13088_CR59
ED O'Brien (13088_CR49) 2000; 29
13088_CR58
13088_CR57
PA Agius (13088_CR37) 2010; 28
J O'Neill (13088_CR52) 2020; 16
DB Mak (13088_CR29) 2013; 49
M Arbyn (13088_CR12) 2018; 5
J O'Neill (13088_CR54) 2019; 37
C de Martel (13088_CR3) 2017; 141
J O’Neill (13088_CR53) 2019; 44
PJ Smith (13088_CR42) 2016; 34
LJ Whop (13088_CR50) 2016; 122
L Bruni (13088_CR2) 2016; 4
AM Spencer (13088_CR34) 2014; 68
H Ali (13088_CR11) 2017; 206
H Wand (13088_CR46) 2016; 16
M Arbyn (13088_CR1) 2020; 8
M Drolet (13088_CR13) 2019; 394
13088_CR45
13088_CR44
SA Roberts (13088_CR32) 2011; 139
K Sinka (13088_CR35) 2014; 68
B Barbaro (13088_CR31) 2012; 196
A Ross (13088_CR40) 1998; 101
J Lei (13088_CR15) 2020; 383
AA Hussein (13088_CR5) 2017; 82
JM Brotherton (13088_CR48) 2019; 211
H Fisher (13088_CR33) 2014; 36
13088_CR39
JM Brotherton (13088_CR21) 2011; 377
G Ogilvie (13088_CR23) 2010; 7
DM Gertig (13088_CR14) 2013; 11
C de Martel (13088_CR4) 2012; 13
13088_CR43
M Gottvall (13088_CR17) 2009; 14
J Mandal (13088_CR55) 2016; 6
M Watson (13088_CR51) 2014; 38
L Brabin (13088_CR22) 2008; 336
M Brisson (13088_CR56) 2020; 395
JM Walboomers (13088_CR8) 1999; 189
13088_CR28
13088_CR27
HJ Larson (13088_CR38) 2014; 32
13088_CR26
13088_CR25
13088_CR24
M Brisson (13088_CR20) 2016; 1
B Barbaro (13088_CR30) 2014; 38
K Tiley (13088_CR47) 2019; 9
M Pirotta (13088_CR7) 2010; 86
S Arrossi (13088_CR9) 2017; 3
EJ Mavundza (13088_CR61) 2021; 9
References_xml – volume: 16
  start-page: 7
  issue: 1
  year: 2020
  ident: 13088_CR52
  publication-title: Hum Vaccin Immunother
  doi: 10.1080/21645515.2019.1640556
– volume: 377
  start-page: 2085
  issue: 9783
  year: 2011
  ident: 13088_CR21
  publication-title: Lancet (London, England)
  doi: 10.1016/S0140-6736(11)60551-5
– volume: 9
  start-page: 687
  issue: 7
  year: 2021
  ident: 13088_CR61
  publication-title: Vaccines (Basel)
  doi: 10.3390/vaccines9070687
– volume: 86
  start-page: 181
  issue: 3
  year: 2010
  ident: 13088_CR7
  publication-title: Sex Trans Infect
  doi: 10.1136/sti.2009.040188
– volume: 29
  start-page: 813
  issue: 5
  year: 2000
  ident: 13088_CR49
  publication-title: Int J Epidemiol
  doi: 10.1093/ije/29.5.813
– ident: 13088_CR57
– volume: 5
  start-page: e006422
  issue: 5
  year: 2015
  ident: 13088_CR36
  publication-title: BMJ Open.
  doi: 10.1136/bmjopen-2014-006422
– ident: 13088_CR19
– ident: 13088_CR25
– ident: 13088_CR39
  doi: 10.1071/SH09140
– volume: 34
  start-page: 1604
  issue: 13
  year: 2016
  ident: 13088_CR42
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2016.01.061
– volume: 38
  start-page: 419
  issue: 5
  year: 2014
  ident: 13088_CR30
  publication-title: Aust N Z J Public Health
  doi: 10.1111/1753-6405.12218
– ident: 13088_CR44
– volume: 6
  start-page: 5
  issue: 1
  year: 2016
  ident: 13088_CR55
  publication-title: Trop Parasitol
  doi: 10.4103/2229-5070.175024
– volume: 101
  start-page: 970
  issue: 6
  year: 1998
  ident: 13088_CR40
  publication-title: Pediatrics
  doi: 10.1542/peds.101.6.970
– volume: 44
  start-page: 98
  issue: 1
  year: 2019
  ident: 13088_CR53
  publication-title: J Intellect Dev Disabil
  doi: 10.3109/13668250.2017.1310827
– volume: 49
  start-page: 895
  issue: 11
  year: 2013
  ident: 13088_CR29
  publication-title: J Paediatr Child Health
  doi: 10.1111/jpc.12030
– volume: 336
  start-page: 1056
  issue: 7652
  year: 2008
  ident: 13088_CR22
  publication-title: BMJ (Clinical research ed)
  doi: 10.1136/bmj.39541.534109.BE
– volume: 32
  start-page: 2150
  issue: 19
  year: 2014
  ident: 13088_CR38
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2014.01.081
– volume: 394
  start-page: 497
  issue: 10197
  year: 2019
  ident: 13088_CR13
  publication-title: Lancet (London, England)
  doi: 10.1016/S0140-6736(19)30298-3
– ident: 13088_CR59
  doi: 10.1093/pubmed/fdaa164
– volume: 141
  start-page: 664
  issue: 4
  year: 2017
  ident: 13088_CR3
  publication-title: Int J Cancer
  doi: 10.1002/ijc.30716
– ident: 13088_CR45
– volume: 82
  start-page: 115
  year: 2017
  ident: 13088_CR5
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2017.05.026
– ident: 13088_CR24
– ident: 13088_CR58
  doi: 10.18590/mjm.2017.vol3.iss2.8
– volume: 383
  start-page: 1340
  issue: 14
  year: 2020
  ident: 13088_CR15
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1917338
– volume: 1
  start-page: e8
  issue: 1
  year: 2016
  ident: 13088_CR20
  publication-title: Lancet Public Health
  doi: 10.1016/S2468-2667(16)30001-9
– ident: 13088_CR27
  doi: 10.1016/j.vaccine.2021.08.076
– volume: 13
  start-page: 325
  issue: 5
  year: 2000
  ident: 13088_CR41
  publication-title: J Am Board Fam Pract
– volume: 28
  start-page: 4416
  issue: 27
  year: 2010
  ident: 13088_CR37
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2010.04.038
– volume: 9
  start-page: e029087
  issue: 7
  year: 2019
  ident: 13088_CR47
  publication-title: BMJ Open.
  doi: 10.1136/bmjopen-2019-029087
– volume: 8
  start-page: e191
  issue: 2
  year: 2020
  ident: 13088_CR1
  publication-title: Lancet Glob Health
  doi: 10.1016/S2214-109X(19)30482-6
– volume: 395
  start-page: 575
  issue: 10224
  year: 2020
  ident: 13088_CR56
  publication-title: Lancet
  doi: 10.1016/S0140-6736(20)30068-4
– volume: 196
  start-page: 445
  issue: 7
  year: 2012
  ident: 13088_CR31
  publication-title: Med J Aust
  doi: 10.5694/mja11.11360
– volume: 37
  start-page: 272
  issue: 2
  year: 2019
  ident: 13088_CR54
  publication-title: Australia Vaccine
  doi: 10.1016/j.vaccine.2018.11.034
– ident: 13088_CR28
  doi: 10.1007/978-1-4020-5614-7_2685
– volume: 17
  start-page: 1085
  issue: 12
  year: 2018
  ident: 13088_CR18
  publication-title: Expert Rev Vaccines
  doi: 10.1080/14760584.2018.1548282
– volume: 3
  start-page: 611
  issue: 5
  year: 2017
  ident: 13088_CR9
  publication-title: J Glob Oncol
  doi: 10.1200/JGO.2016.008151
– volume: 4
  start-page: e453
  issue: 7
  year: 2016
  ident: 13088_CR2
  publication-title: Lancet Glob Health
  doi: 10.1016/S2214-109X(16)30099-7
– volume: 139
  start-page: 400
  issue: 3
  year: 2011
  ident: 13088_CR32
  publication-title: Epidemiol Infect
  doi: 10.1017/S095026881000066X
– volume: 16
  start-page: 600
  year: 2016
  ident: 13088_CR46
  publication-title: BMC Public Health
  doi: 10.1186/s12889-016-3195-6
– volume: 68
  start-page: 571
  issue: 6
  year: 2014
  ident: 13088_CR34
  publication-title: J Epidemiol Community Health
  doi: 10.1136/jech-2013-202629
– volume: 17
  start-page: 7997
  issue: 21
  year: 2020
  ident: 13088_CR60
  publication-title: Int J Environ Res Public Health
  doi: 10.3390/ijerph17217997
– ident: 13088_CR16
– volume: 211
  start-page: 31
  issue: 1
  year: 2019
  ident: 13088_CR48
  publication-title: Med J Aust
  doi: 10.5694/mja2.50221
– volume: 346
  start-page: f2032
  year: 2013
  ident: 13088_CR10
  publication-title: Brit Med J.
  doi: 10.1136/bmj.f2032
– volume: 38
  start-page: 91
  issue: 1
  year: 2014
  ident: 13088_CR51
  publication-title: Aust N Z J Public Health
  doi: 10.1111/1753-6405.12149
– volume: 7
  start-page: e1000270
  issue: 5
  year: 2010
  ident: 13088_CR23
  publication-title: PLoS Med 
  doi: 10.1371/journal.pmed.1000270
– volume: 14
  start-page: 399
  issue: 6
  year: 2009
  ident: 13088_CR17
  publication-title: Eur J Contracept Reprod Health Care
  doi: 10.3109/13625180903229605
– volume: 122
  start-page: 1560
  issue: 10
  year: 2016
  ident: 13088_CR50
  publication-title: Cancer
  doi: 10.1002/cncr.29954
– ident: 13088_CR26
– volume: 36
  start-page: 36
  issue: 1
  year: 2014
  ident: 13088_CR33
  publication-title: J Public Health (Oxf)
  doi: 10.1093/pubmed/fdt042
– volume: 206
  start-page: 204
  issue: 5
  year: 2017
  ident: 13088_CR11
  publication-title: Med J Aust
  doi: 10.5694/mja16.00597
– volume: 11
  start-page: 227
  year: 2013
  ident: 13088_CR14
  publication-title: BMC Med
  doi: 10.1186/1741-7015-11-227
– volume: 5
  start-page: Cd009069
  issue: 5
  year: 2018
  ident: 13088_CR12
  publication-title: Cochrane Database Syst Rev
– volume: 189
  start-page: 12
  issue: 1
  year: 1999
  ident: 13088_CR8
  publication-title: J Pathol
  doi: 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
– ident: 13088_CR43
– volume: 13
  start-page: 607
  issue: 6
  year: 2012
  ident: 13088_CR4
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(12)70137-7
– volume: 16
  start-page: 763
  issue: 6
  year: 2013
  ident: 13088_CR6
  publication-title: J Med Econ
  doi: 10.3111/13696998.2013.793691
– volume: 68
  start-page: 57
  issue: 1
  year: 2014
  ident: 13088_CR35
  publication-title: J Epidemiol Commun Health
  doi: 10.1136/jech-2013-202620
SSID ssj0017852
Score 2.4267085
Snippet Background In Australia in 2017, 89% of 15-year-old females and 86% of 15-year-old males had received at least one dose of the HPV vaccine. However,...
In Australia in 2017, 89% of 15-year-old females and 86% of 15-year-old males had received at least one dose of the HPV vaccine. However, considerable...
Background In Australia in 2017, 89% of 15-year-old females and 86% of 15-year-old males had received at least one dose of the HPV vaccine. However,...
In Australia in 2017, 89% of 15-year-old females and 86% of 15-year-old males had received at least one dose of the HPV vaccine. However, considerable...
Abstract Background In Australia in 2017, 89% of 15-year-old females and 86% of 15-year-old males had received at least one dose of the HPV vaccine. However,...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 822
SubjectTerms Adolescence
Adolescent
Adolescents
Age
Australia - epidemiology
Biostatistics
Cervical cancer
Curricula
Educational aspects
Environmental Health
Epidemiology
Female
Girls
Health equity
Health promotion
HPV vaccines
Human papillomavirus
Humans
Immunisation programs
Immunization
Male
Medical screening
Medicine
Medicine & Public Health
Methods
Papillomavirus Infections - prevention & control
Papillomavirus Vaccines
Population
Population statistics
Primary prevention
Public Health
School-based
Schools
Special education
Students
Teenagers
Vaccination
Vaccine
Vaccines
Variation
Warts
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NaxUxEA_SkyCi1o_VKhEED7o0u_naPVaxPATFg5V6CvlaLJR9pbtP-uc7k-w-u5XWS6-bSTaZmWR-SWYmhLxxNewBQiVLUGBVChlFab2OJXMyNpx1ognJ2-KrWh2Jz8fy-NJTX-gTltMDZ8btixCUtVCrjVY46VwVQgCj20UeaxVT6B5r2byZmu4PdCPrOUSmUfsDrMLoGgQbL1izQTcuFmYoZev_d02-ZJSuOkxeuTVNxujwAbk_oUh6kHv_kNyJ_SNyLx_B0RxZtEt-fknnf9AAHVKuTXqKHkLUjvmVKwyaouhaTsc1HTZniMQnyhKNW6Crbz_ob-v9ST4ypJMz1_CYHB1--v5xVU4vKZReMT2WUWutmG8AGzRRVLpqtQPDHNqogKuN4DC02gbHdS24E07VTHot6yh9dKzt-BOy06_7-IxQjrmQ6pZ1nUXwESyzvOPKQSMgJK8LUs2MNX5KM46vXZyatN1olMnCMCAMk4RhLgryblvnLCfZuJH6A8prS4kJstMHUBszqY35n9oU5C1K2-A0hu55O0UjwCAxIZY50IiFW1jeCrK3oITp55fFs76YafoPBlCPSs7D8J_X22KsiS5tfVxvkEZKgJtAVZCnWb22Q-JSqAbYWxC9ULzFmJcl_cmvlBy8BUiSar6fVfRvt67n6fPb4OkLchfgpMS7tlrukZ3xfBNfAmQb3as0O_8A0Vc-VA
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Scholars Portal Open Access Journals
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELaqckFCiDehBRkJiQMEEj-TA0IFUa2QQBxYVE6WX4FKq2y7m0Xl3zPjJFtSSq_rcdbzsj_b4xlCnjkGe4BQyhwMWOVCRpFbr2NeOBkrXjSiCina4rOazcXHI3m0Q8ZyR4MA15du7bCe1Hy1eHV2-vstOPyb5PCVer2GORYDf2BbBTMyaB4w5bV0X4ShfOL8VkFXko0PZy7tN1mcUg7_f2fqv5aqi2GUF-5S0xJ1eIvcHLAlPeiN4TbZie0dcqM_mKP9e6O75PundCoIH6DrlIGTLjBuiNqur32FT6koBpzTbknXmxMUzUCZ45IX6OzLN_rLen_cHyTSIcRrfY_MDz98fT_Lh_oKuVeF7vKotVaFrwAxVFGUuqy1g-U61FFFKyrBgTVmg-OaCe6EU6yQXksWpY-uqBt-n-y2yzY-JJRjhiRWF01jEZIEW1jecOXgI6BwrzNSjoI1fkg-jjUwFiZtQiplemUYUIZJyjBnGXmx7XPSp964kvod6mtLiWmz0w_L1Q8zeKERIShrYUQ1MOikc2UIARBcE3lkKtYZeY7aNmhuMDxvhzcKwCSmyTIHGhFyDZNeRvYnlOCUfto82osZbdoAFlIppBj-5-m2GXtioFsblxukkRJAKFBl5EFvXluWuBSqAvFmRE8Mb8LztKU9_plShtcAVFLPl6OJng_r_zJ9dDUXe-Q6Q-cpRM7kPtntVpv4GCBa554kv_sD4mA3Zg
  priority: 102
  providerName: Scholars Portal
– databaseName: Springer Nature OA Free Journals
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bi9UwEA6ygggiut6qq0QQfNBim2v7uB5cDsKKD66sTyG34sLSs9ge8ec7k-bU7XoB30ozSTOZmeRLMzMh5IVjsAcItSxBgVUpZBSl9TqWlZOx4VUnmpC8LT6o9Yl4fypPc5ocjIW5fH5fN-rNAPMnOvXAlglmW5Aq4MXrEh5Rm1dqNZ8Y6EayXVDMH-stFp6Un__3WfjSMnTVRfLKOWlafo7ukNsZN9LDSdB3ybXY75Mbx_lkfJ_cmv6_0Sms6B75cpx-_kFbdEiJNuk5ugdRO05XXGHEFEW_cjpu6LC9QBieKUtc2QJdf_xMv1sPzSfh0ezJNdwnJ0fvPq3WZb5GofSq0mMZtdaq8g0AgyaKWtetdrAqhzaqaEUjOHDJbHBcM8GdcIpV0mvJovTRVW3HH5C9ftPHR4RyTITE2qrrLCKPYCvLO64cNAJy9bog9W6Mjc85xvGqi3OT9hqNMpNcDMjFJLmYHwV5Nde5mDJs_JP6LYpupsTs2OkFKI3JxmZECMpa6FELDDrpXB1CAKDWRR6Zim1BXqLgDdowdM_bHIoATGI2LHOoEQi3MLcV5GBBCbbnl8U71THZ9gcDkEclz2H4zvO5GGuiP1sfN1ukkRKwJlAV5OGkaTNLXArVwPAWRC90cMHzsqQ_-5oyg7eAR1LN1ztt_dWtv4_p4_8jf0JuMrSrSpRMHpC98ds2PgVkNrpnySR_AqtRMIo
  priority: 102
  providerName: Springer Nature
Title Measuring school level attributable risk to support school-based HPV vaccination programs
URI https://link.springer.com/article/10.1186/s12889-022-13088-x
https://www.ncbi.nlm.nih.gov/pubmed/35468743
https://www.proquest.com/docview/2666667699
https://www.proquest.com/docview/2655560676
https://pubmed.ncbi.nlm.nih.gov/PMC9036743
https://doaj.org/article/4dd6aa30f9ea4b5bb1ddd727fe3e26e9
Volume 22
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1da9swULTpy2CMfddbFzQY7GEztWV9-WGMJDQLg4ZSlpHtRViWvBVKkjXJ6M_fnWync8f6Ikh0Mjrd6e50Ot0R8sYyOAO4VMTAwDLmwvO4KJWPEyu8zpKKaxeiLaZyMuOf52K-R6btWxgMq2xlYhDUblmij_wYFIkM8Zj5x9WvGKtG4e1qW0KjaEoruA8hxdg-OQCRLJIeORieTM_Od_cKSgvWPp3R8ngN0hlDhuBABrIceOa6o55CFv9_ZfVfyup2IOWt29SgpMYPyYPGuqSDmh0ekT2_eEzu1645Wr84ekK-nQa_IHyArkMOTnqJkUO02NTVr_AxFcWQc7pZ0vV2hRZ6Axmj0nN0cvaV_obFuKhdibQJ8lo_JbPxyZfRJG4qLMSlTNQm9kopmZQabAbtearSXFlQ2C730hdc8wxQY4WzmWI8s9xKlohSCeZF6W2SV9kz0lssF_6Q0AxzJLE8qaoCjRJXJEVWZdLCR4DkpYpI2i6sKZv041gF49KEY4iWpiaGAWKYQAxzHZF3uzGrOvnGndBDpNcOEhNnhz-WVz9Msw8Nd04WBcwoBwStsDZ1zoENV_nMM-nziLxFahvc3jC9smheKQCSmCjLDBTayDmIvYgcdSBhW5bd7pZfTCMW1uaGiSPyeteNIzHUbeGXW4QRAsxQgIrI85q9dihlgksNyxsR1WG8Ds7dnsXFz5A0PAdTJYx837LozbT-v6Yv7sbiJbnHcPMkPGbiiPQ2V1v_Coy0je2TfTVX0OpRiu34U7_Zi_BrJEf94PyA9pRraM-H36GdscEftHJB0Q
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3LbtQwcFS2B5AQ4k2ggJFAHCBq1vEjOVSohVZb-lCFWtSeTBw7UKnaXbq7UH6Ob2PGSbakiN56jcdW7Hnb8wB4aTn6AK4vYyRgFQvpRVyU2seJlT5Lk0pkLkRb7KrBgfh4KA8X4HebC0Nhla1MDILajUq6I19GRaJCPGb-bvw9pq5R9LrattAomtYKbiWUGGsSO7b8r5_owk1WNj8gvl9xvrG-_34QN10G4lIlehp7rbVKygz1ZuZFX_dzbVFpudwrX4hMpN6VvHA21VykVljFE1lqyb0svU3yKsV1r8GioAuUHiyure_ufZq_Y-hM8jZVJ1PLE9QGFKKEDiDqDqTRs446DF0D_tUNfynHi4GbF15vg1LcuA23GmuWrdbkdwcW_PAu3KyvAlmd4XQPjnbCPSQuwCah5ic7oUglVkzrbluUvMUoxJ1NR2wyG5NH0EDGpGQdG-x9Zj_w8I_rq0vWBJVN7sPBlZz1A-gNR0P_CFhKNZl4nlRVQUaQK5IirVJlcREksVJH0G8P1pRNuXPqunFigtuTKVMjwyAyTECGOYvgzXzOuC72cSn0GuFrDkmFusOH0elX0_C9Ec6posA_ynGDVlrbd86hzVj51HPl8wheE7YNiRP8vbJosiJwk1SYy6xqsslzFLMRLHUgUQyU3eGWXkwjhibmnGkieDEfppkUWjf0oxnBSIlmL0JF8LAmr_mWkKZVhscbge4QXmfP3ZHh8bdQpDxH0yjMfNuS6Plv_f9MH1--i-dwfbC_s222N3e3nsANToyUiJjLJehNT2f-KRqIU_us4UIGX66a8f8APAJ2mg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Zb9QwELZQkSokhKAcDRQwEhIPEDXxmTwux2o5WvWBReXJsmMHkKrsqskifj4zTjY05ZB4XY-9Ho9n5nM8MybkqWNwBvC5TGEDq1TIIFJb6ZBmToaCZ7UofIy2OFaLpXh3Kk8vZPHHaPftlWSf04BVmprucO3rXsULddiCVcVQHzhIgQ0GWQOKvCrAV2NQ15LNxnsEXUi2TZX5Y7-JO4pV-3-3zRec0-XAyUu3p9EpzW-SGwOapLNe_LfIldDskd2j4b58j1zvv8rRPtnoNvl8FD8Jwli0jeU36RkGDVHb9Q9fYR4VxWhz2q1ou1kjOB8oU_R3ni5OPtHvtoLho0jpEN_V3iHL-ZuPrxbp8LhCWqlMd2nQWqusKgAuFEHkOi-1A1_ty6CCFYXgwCWz3nHNBHfCKZbJSksWZBVcVtb8LtlpVk3YJ5RjeSRWZnVtEY94m1lec-VgEJB2pROSb9fYVEPlcXwA48zEE0ihTC8XA3IxUS7mR0Kej33Wfd2Nf1K_RNGNlFgzO_6wOv9iBhU0wntlLcyoBAaddC733gN8qwMPTIUyIc9Q8AY1G6ZX2SFBAZjEGllmphEel2DxEnIwoQSNrKbN261jBovQGgBCKsYTw_88GZuxJ0a5NWG1QRopAYECVULu9TttZIlLoQpY3oToyR6c8Dxtab59jfXCS0ApseeL7W79Na2_r-n9_yN_THZPXs_Nh7fH7x-QawxVLBMpkwdkpzvfhIcA3Tr3KGrnT8QTO98
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Measuring+school+level+attributable+risk+to+support+school-based+HPV+vaccination+programs&rft.jtitle=BMC+public+health&rft.au=Vujovich-Dunn%2C+C&rft.au=Wand%2C+H&rft.au=Brotherton%2C+J+M+L&rft.au=Gidding%2C+H&rft.date=2022-04-25&rft.pub=BioMed+Central&rft.eissn=1471-2458&rft.volume=22&rft.spage=1&rft_id=info:doi/10.1186%2Fs12889-022-13088-x
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2458&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2458&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2458&client=summon